Compare Procter & Gamble Health with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs PFIZER - Comparison Results

PROCTER & GAMBLE HEALTH     Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PROCTER & GAMBLE HEALTH PFIZER PROCTER & GAMBLE HEALTH/
PFIZER
 
P/E (TTM) x 41.9 36.8 114.0% View Chart
P/BV x 4.5 6.2 72.0% View Chart
Dividend Yield % 10.6 0.6 1,925.9%  

Financials

 PROCTER & GAMBLE HEALTH   PFIZER
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Dec-18
PFIZER
Mar-19
PROCTER & GAMBLE HEALTH/
PFIZER
5-Yr Chart
Click to enlarge
High Rs3,5493,840 92.4%   
Low Rs1,3012,080 62.6%   
Sales per share (Unadj.) Rs511.4455.0 112.4%  
Earnings per share (Unadj.) Rs61.393.8 65.4%  
Cash flow per share (Unadj.) Rs74.0109.4 67.7%  
Dividends per share (Unadj.) Rs440.0022.50 1,955.6%  
Dividend yield (eoy) %18.10.8 2,386.8%  
Book value per share (Unadj.) Rs927.8658.2 141.0%  
Shares outstanding (eoy) m16.6045.75 36.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.76.5 72.9%   
Avg P/E ratio x39.631.6 125.4%  
P/CF ratio (eoy) x32.827.1 121.1%  
Price / Book Value ratio x2.64.5 58.1%  
Dividend payout %717.924.0 2,992.3%   
Avg Mkt Cap Rs m40,257135,420 29.7%   
No. of employees `0001.12.6 43.1%   
Total wages/salary Rs m1,3133,238 40.5%   
Avg. sales/employee Rs Th7,486.77,911.4 94.6%   
Avg. wages/employee Rs Th1,157.61,230.9 94.0%   
Avg. net profit/employee Rs Th897.21,630.7 55.0%   
INCOME DATA
Net Sales Rs m8,49020,815 40.8%  
Other income Rs m2441,674 14.6%   
Total revenues Rs m8,73422,489 38.8%   
Gross profit Rs m1,4825,712 25.9%  
Depreciation Rs m211714 29.6%   
Interest Rs m073 0.0%   
Profit before tax Rs m1,5146,599 22.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m660-   
Tax Rs m5632,309 24.4%   
Profit after tax Rs m1,0174,291 23.7%  
Gross profit margin %17.527.4 63.6%  
Effective tax rate %37.135.0 106.2%   
Net profit margin %12.020.6 58.1%  
BALANCE SHEET DATA
Current assets Rs m15,34327,167 56.5%   
Current liabilities Rs m1,9608,917 22.0%   
Net working cap to sales %157.687.7 179.8%  
Current ratio x7.83.0 256.9%  
Inventory Days Days4968 71.9%  
Debtors Days Days2830 94.5%  
Net fixed assets Rs m1,2098,862 13.6%   
Share capital Rs m166458 36.3%   
"Free" reserves Rs m15,23529,656 51.4%   
Net worth Rs m15,40130,113 51.1%   
Long term debt Rs m025 0.0%   
Total assets Rs m17,59539,400 44.7%  
Interest coverage xNM91.5-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.5 91.3%   
Return on assets %5.811.1 52.2%  
Return on equity %6.614.2 46.4%  
Return on capital %10.322.1 46.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m1,636428 382.0%   
Fx outflow Rs m4,368786 555.5%   
Net fx Rs m-2,732-358 762.9%   
CASH FLOW
From Operations Rs m-1,304978 -133.3%  
From Investments Rs m12,697351 3,615.4%  
From Financial Activity Rs m-301-1,099 27.4%  
Net Cashflow Rs m11,093231 4,806.3%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 51.8 63.9 81.1%  
Indian inst/Mut Fund % 18.2 7.5 242.7%  
FIIs % 1.0 4.9 20.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 23.7 122.8%  
Shareholders   28,591 85,207 33.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PROCTER & GAMBLE HEALTH With:   FULFORD INDIA  VENUS REMEDIES  IPCA LABS  WOCKHARDT  AUROBINDO PHARMA  

Compare PROCTER & GAMBLE HEALTH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 143 Points Lower; Banking and Finance Stocks Witness Selling(Closing)

Indian share markets witnessed selling pressure throughout the day today, tracking weak global cues as coronavirus cases continue to surge across the world.

Related Views on News

PFIZER Announces Quarterly Results (3QFY20); Net Profit Up 5.4% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, PFIZER has posted a net profit of Rs 1 bn (up 5.4% YoY). Sales on the other hand came in at Rs 5 bn (up 4.7% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PFIZER Announces Quarterly Results (2QFY20); Net Profit Up 61.0% (Quarterly Result Update)

Oct 29, 2019 | Updated on Oct 29, 2019

For the quarter ended September 2019, PFIZER has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 6 bn (up 9.1% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

A Warning for Traders: Don't Get Addicted to Hopium(Fast Profits Daily)

Jun 30, 2020

If you are a trader, you must watch out for this dangerous addiction.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

PROCTER & GAMBLE HEALTH SHARE PRICE


Jul 10, 2020 (Close)

TRACK PROCTER & GAMBLE HEALTH

  • Track your investment in PROCTER & GAMBLE HEALTH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PROCTER & GAMBLE HEALTH

PROCTER & GAMBLE HEALTH 8-QTR ANALYSIS

COMPARE PROCTER & GAMBLE HEALTH WITH

MARKET STATS